Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components

Fekete, Natalie; Gadelorge, Mélanie; Fürst, Daniel E.; Maurer, Caroline; Dausend, Julia; Fleury-Cappellesso, Sandrine; Mailänder, Volker; Lotfi, Ramin; Ignatius, Anita; Sensebé, Luc; Bourin, Philippe; Schrezenmeier, Hubert; Rojewski, Markus

doi:10.3109/14653249.2012.655420

Cited by 248 publications

(273 citation statements)

References 65 publications

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…Moreover, it represents a good GMP-compliant alternative to animal serum for MSC clinical production confirming the recent data reported in the literature (18,36,37).…”

Section: Discussionsupporting

confidence: 74%

“…Moreover, it is being established as a safe and efficient MSC culture supplement for robust MSC cultivation, thus offering certain advantages as potential FBS substitutes (18)(19)(20)(21). Analyses of platelet lysates, and subcellular fractions have shown that numerous bioactive molecules are stored within distinct platelet organelles including adhesive proteins, coagulation factors, mitogens, protease inhibitors, and proteoglycans (22).…”

Section: List Of Abbreviationsmentioning

confidence: 99%

See 1 more Smart Citation

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Moreover, it represents a good GMP-compliant alternative to animal serum for MSC clinical production confirming the recent data reported in the literature (18,36,37).…”

Section: Discussionsupporting

confidence: 74%

Section: List Of Abbreviationsmentioning

confidence: 99%

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

et al. 2014

View full text Add to dashboard Cite

show abstract

“…For all experiments, MSC were cultured in clinical-grade a-modified Eagle's medium (a-MEM) (PAA) supplemented with 5% of clinical-grade human platelet lysate kindly provided by Markus T. Rojewski, 19 0.5% of ciprofloxacin (Bayer Pharma) and 1 U/mL of heparin (Sanofi-Aventis). Cells were cultured in a humidified atmosphere at 37°C and 5% CO 2 .…”

Section: Msc Culturementioning

confidence: 99%

“…28 Moreover, the medium and the process of MSC culture are critical as these parameters could influence MSC properties. 49 In this study, we used (1) human AM agreed for clinical use, (2) GMP culture medium supplemented with human platelet lysate produced in GMP condition and extensively studied by Fekete and colleagues 19 for ex vivo MSC expansion, (3) clinical-grade MSC from two different sources: BM 19 and AT. 21 Overall, our data showed that this construction is feasible and releases important cytokines and growth factors that are important in regulating wound healing and tissue regeneration.…”

mentioning

confidence: 99%

In VitroCharacterization of Patches of Human Mesenchymal Stromal Cells

Roux

Bodivit

Bartis

et al. 2015

Tissue Engineering Part A

View full text Add to dashboard Cite

Stem cells may represent an excellent strategy to improve the healing of skin ulcers. Today the administration mode of stem cells to skin defects remains unsatisfactory. Delivering stem cells with topical treatments represents a new strategy and answering the patients' need. Mesenchymal stromal cells (MSC) have been shown to improve wound healing of cutaneous lesions and amniotic membrane (AM) is known to represent a natural scaffold for cells. The aim of this study is to develop a tissue-engineered product combining MSC and AM for clinical use. In this work we investigated whether the stromal matrix of intact human AM could constitute a scaffold for human MSC derived from either bone marrow (BM) or adipose tissue (AT). For this purpose, clinical-grade AM, MSC, and culture medium were used. We performed experiments of short-term adherence and proliferation for 15 days after the seeding of the cells. Morphological aspects and secretion profiles of MSC onto AM were studied, respectively, by scanning electron microscopy and Luminex analysis. Results demonstrated that the stromal matrix allow the adherence in much greater amount of MSC from BM or AT compared to 2D material. Experiments of proliferation showed that both kinds of MSC could proliferate on the stromal matrix and remain viable 15 days after the seeding of the cells. The 3D analysis of MSC culture demonstrated that both types of MSC invaded the stromal matrix and grew in multiple layers while retaining their fibroblastic morphology. By studying the secretion profile of MSC onto the stromal matrix, we found that both kinds of MSC secrete important cytokines and growth factors for wound healing of cutaneous lesions, such as vascular endothelial growth factor, hepatocyte growth factor, and basic fibroblast growth factor. In conclusion, these results suggest that the stromal matrix of AM seeded with MSC represents a bioactive scaffold that should be evaluated in patients with a nonhealing cutaneous wound.

show abstract

“…Further, the PDGF could regulate the wound healing and tissue regeneration by regulating the recruitment of fibroblasts and the precursor MSC and stimulating the generation of hydrogen peroxide which is required for cell migration 43, 44. It can be speculated that EGF and PDGF can be regarded as the safe mediums for MSC expansion and for clinical purposes 45, 46.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‐98 regulates osteogenic differentiation of human bone mesenchymal stromal cells by targeting BMP2

Zhang

Zhu

et al. 2016

J Cellular Molecular Medi

View full text Add to dashboard Cite

To study the effects of microRNA‐98 (miR‐98) on human bone mesenchymal stromal cells (hBMSCs). The patients undergoing hip arthroplasty were selected by inclusion/exclusion criteria for this study. The extracted hBMSCs were detected of osteogenic differentiation by alizarin red S staining, and of cell phenotype by flow cytometry. Bioinformatics, dual luciferase report, western blotting, RT‐PCR and immunoblotting were used in our study. The hBMSCs were divided into miR‐98 mimics, miR‐98 negative control (NC), miR‐98 inhibitors, Mock and miR‐98 inhibitors + siBMP2 groups. Human bone mesenchymal stromal cells were extracted and purified in vitro and had specific cytological morphology, surface markers and abilities of self‐renewal and differentiation. Compared with the NC group and Mock group, the miR‐98 mimics group showed increased miR‐98 level while the miR‐98 inhibitors group decreased miR‐98 level (both P < 0.01). Dual luciferase reporter showed BMP2 was the target gene of miR‐98. The levels of mRNA and protein expression of BMP2, protein expression of RUNX2, alkaline phosphatase activity and osteocalcin content significantly decreased in the miR‐98 mimics group while increased in the miR‐98 inhibitors group and showed no changes in the NC group and Mock group (all P < 0.05). The miR‐98 mimics group showed obviously declined stained red particles and the miR‐98 inhibitors group showed opposite result. After lowering the expression of miR‐98, osteogenic differentiation ability of hBMSCs rose, which was weakened by the transfection with siBMP2. miR‐98 may regulate osteogenic differentiation of hBMSCs by targeting BMP2.

show abstract

Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components

Cited by 248 publications

References 65 publications

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

In VitroCharacterization of Patches of Human Mesenchymal Stromal Cells

MicroRNA‐98 regulates osteogenic differentiation of human bone mesenchymal stromal cells by targeting BMP2

Contact Info

Product

Resources

About